WEED, Inc. (OTC:BUDZ) to Present its $40 Million RegA+ Offering at Starlight Capital’s Investment & Technology Conference tomorrow March 25th, 2021
Press Release | 03/24/2021
TUCSON, AZ / ACCESSWIRE / March 24, 2021 / WEED, Inc. (OTCQB:BUDZ) ("WEED" or the "Company"), one of the top cannabis and hemp bioresearch companies based in the USA, announced today that WEED Chief Executive Officer Glenn E. Martin will present at Starlight Capital's virtual conference tomorrow, March 25th between 12 noon and 2PM EDT. Martin will announce WEED's opportunities to invest in a new $40M financing round in BUDZ under Regulation A, Tier 2 as recently qualified by the Securities and Exchange Commission (See WEED, Inc. Offering pitchdeck Here.)
Thanks to the Company's extensive R&D history in cannabis and hemp markets, WEED is on the verge of a major expansion. Martin will describe the Company's history and its current and targeted real estate and IP assets and other opportunities as well as the Company's plans post-COVID. The Company is pleased to announce its new program to expand its global research & development program, which currently includes WEED Inc. subsidiaries and partners in Australia, Israel, Hong Kong, and the USA. At the same time, the Company will launch an aggressive program to identify, acquire, and integrate domestic and foreign assets and businesses that will most directly benefit from the continued opening up of cannabis markets worldwide - principally, retail and wholesale producers of cannabis and hemp plants and their derivative products.
"All indications are that there may never be a better time to go ‘all-in' on the future of Cannabis and Hemp markets, and we want the public to join us," said Glenn E. Martin, CEO of WEED, Inc. "We created this Reg A+ offering so that all investors - not just the big, accredited guys - can be part of the growth and expansion we expect for 2021 and beyond. This is where stoners Meet Wall Street."
Investors may sign up at no charge here: https://www.starlightcapital.co/event-info/starlight-capital-technology-investment-forum
WEED, Inc.'s Subsidiaries
WEED Israel (Cannabis) Ltd. "After over a year of putting human clinical trials and product development on hold due to COVID, Israel is poised and anxious to build out our global brands in both pharmaceutical and non-pharmaceutical categories, starting with women's health and veterans' ailments (PTSD) to healthy green alternative medicines" stated Elliot Kwestel, Managing Director of WEED Israel (Cannabis) Ltd. based outside Jerusalem. Kwestel further commented, "WEED Israel looks to enrich our lives for generations to come."
WEED Australia Ltd. and The Cannabis Institute of Australia (C.I.A.), our Australian non-profit arm, based in Queensland on the Gold Coast. Managing Director Patrick Brodnik commented, "With the new rules just out governing cannabis in Australia and the announcement on 1st. February 2021 to allow over-the-counter CBD medicines in pharmacies, WEED Australia congratulates USA's new administration of President Joe Biden and its historic vote for Vice President Kamala Harris." Managing Director Brodnik continues, "We expect the future of decriminalizing cannabis and hemp in the USA to prove to be a giant leap forward for global cannabis legalization."
WEED Hong Kong Ltd. Director Nicole Breen agrees, "The pandemic has affected all of us on a worldwide basis. Healing our planet with natural therapies, treatments and eventual "cures" utilizing natures' own Cannabaceae plant with its many properties, both with high tetrahydrocannabinol (THC) and cannabidiol (CBD) compounds, I believe will change the force of medicine forever in the years to come."
WEED, Inc., a Nevada corporation (the Company, WEED, we, or our) is offering (the "Offering") up to a maximum of 40,000,000 units ("Units"), with each Unit consisting of one (1) share of our common stock, par value $0.001 ("Common Stock") and one (1) warrant to purchase (1) share of our common stock, at a purchase price of $1.00 per Unit. The exercise price on the warrant will be 150% of the price of the Unit sold to the investor and cannot be exercised by the holder until at least twelve months after issuance.
The Units are being offered pursuant to Regulation A of Section 3(b) of the Securities, as amended, for Tier 2 offerings, by management on a "best-efforts" basis directly to purchasers who satisfy the requirements set forth in Regulation A.
Securities are offered and distributed pursuant to Regulation A+ through Dalmore Group LLC, a registered broker dealer, member FINRA (www.FINRA.org) and member SIPC (www.SIPC.org). These securities being offered are highly speculative due to the nature of the investment, and the fact that cannabis remains a controlled substance at the Federal level according to Schedule 1 of the Controlled Substances Act of 1970.
Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. Investors should carefully read the risk factors and disclosures contained in our offering circular before making any decision to invest in our company.
Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Legal Notice
This press release is for information purposes only and does not constitute an offer or sale of the securities referenced herein. Any such offer will only be made in compliance with applicable state and federal securities laws pursuant to Regulation A, Tier 2 of the Securities Act of 1933. A link to the qualified offering circular and related offering documents is attached hereto and all prospective investors should carefully review these materials, which includes important disclosures and risk factors associated with an investment in WEED, Inc. These securities have not been recommended by the Securities and Exchange Commission or any state securities commission or regulatory authority, nor has any commission or regulatory confirmed the accuracy of the information contained the offering materials.
The information is provided for convenience only, is not investment advice and may not be relied upon in considering an investment in WEED, Inc. No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research. No representation or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment. In addition, prospective investors are encouraged to consult with their financial, tax, accounting or other advisors to determine whether an investment in WEED, Inc. is suitable for them.
Media Contact:
Glenn E. Martin, CEO
1-520-818-8582
Glenn@WEEDincUSA.com
Investor Contact:
Bryan Emerson
Great Point Capital
200 W. Jackson Blvd., Ste 1000
Chicago, IL 60606
bemerson@gpcchi.com
First Apex International
Scott Biddick, Managing Director
Investors@WEEDincUSA.com
WEED, Inc. Launches $40 Million Offering To Fuel Expansion, Acquisitions
Press Release | 02/24/2021
TUCSON, AZ / ACCESSWIRE / February 24, 2021 / WEED, Inc. (OTCQB:BUDZ) ("WEED" or the "Company"), one of the top cannabis and hemp bioresearch companies in the USA, announced today the launch of a new $40M financing round under Regulation A, Tier 2 as recently qualified by the Securities and Exchange Commission (See WEED, Inc. Offering Circular Here.)
Thanks to the Company's extensive R&D history and the current state of worldwide politics and public opinion, WEED's management believes the cannabis and hemp markets are ready for another wave of expansion and growth. The Company is pleased to announce its new program to expand its global research & development program, which currently includes WEED Inc. subsidiaries in Australia, Israel, Hong Kong, and the USA. At the same time, the Company will launch an aggressive program to identify, acquire, and integrate domestic and foreign assets and businesses that will most directly benefit from the continued opening up of cannabis markets worldwide - principally, retail and wholesale producers of cannabis and hemp plants and their derivative products.
"All indications are that the Cannabis and Hemp markets have momentum and we want to give the opportunity for the public to join us," said Glenn E. Martin, CEO of WEED, Inc. "We created this Reg A+ offering so that all investors - not just the big, accredited guys - can be part of the growth and expansion we expect for 2021 and beyond. It's where stoners meet Wall Street."
WEED, Inc.'s Subsidiaries
WEED Israel (Cannabis) Ltd. "After over a year of putting human clinical trials and product development on hold due to COVID, WEED Israel is poised and anxious to build out our global brands in both pharmaceutical and non-pharmaceutical categories, starting with women's health and veterans' ailments (PTSD) to healthy green alternative medicines" stated Elliot Kwestel, Managing Director of WEED Israel (Cannabis) Ltd. based outside Jerusalem. Kwestel further commented, "WEED Israel looks to enrich our lives for generations to come."
WEED Australia Ltd. and The Cannabis Institute of Australia (C.I.A.), our Australian non-profit arm, based in Queensland on the Gold Coast. Managing Director Patrick Brodnik commented, "With the new rules just out governing cannabis in Australia and the announcement on 1st. February 2021 to allow over-the-counter CBD medicines in pharmacies, WEED Australia is excited for the future, and we congratulate the USA's new administration of President Joe Biden and its historic vote for Vice President Kamala Harris." Managing Director Brodnik continues, "The future of decriminalizing cannabis and hemp in the USA shall prove to be a giant leap forward for global cannabis legalization."
WEED Hong Kong Ltd. Director Nicole Breen agrees, "The pandemic has affected all of us on a worldwide basis. Healing our planet with natural therapies, treatments and eventual "cures" utilizing natures' own Cannabaceae plant with its many properties, both with high tetrahydrocannabinol (THC) and cannabidiol (CBD) compounds, I believe will change the force of medicine forever in the years to come."
WEED, Inc., a Nevada corporation (the Company, WEED, we, or our) is offering (the "Offering") up to a maximum of 40,000,000 units ("Units"), with each Unit consisting of one (1) share of our common stock, par value $0.001 ("Common Stock") and one (1) warrant to purchase (1) share of our common stock, at a purchase price of $1.00 per Unit. The exercise price on the warrant will be 150% of the price of the Unit sold to the investor and cannot be exercised by the holder until at least twelve months after issuance.
The Units are being offered pursuant to Regulation A of Section 3(b) of the Securities Act of 1933, as amended, for Tier 2 offerings, by management on a "best-efforts" basis directly to purchasers who satisfy the requirements set forth in Regulation A.
Securities are offered and distributed pursuant to Regulation A+ through Dalmore Group LLC, a registered broker dealer, member FINRA (www.FINRA.org) and member SIPC (www.SIPC.org). These securities being offered are highly speculative due to the nature of the investment, and the fact that cannabis remains a controlled substance at the Federal level according to Schedule 1 of the Controlled Substances Act of 1970.
Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation. Investors should carefully read the risk factors and disclosures contained in our offering circular before making any decision to invest in our company.
Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Legal Notice
This press release is for information purposes only and does not constitute an offer or sale of the securities referenced herein. Any such offer will only be made in compliance with applicable state and federal securities laws pursuant to Regulation A, Tier 2 of the Securities Act of 1933. A link to the qualified offering circular and related offering documents is attached hereto and all prospective investors should carefully review these materials, which includes important disclosures and risk factors associated with an investment in WEED, Inc. These securities have not been recommended by the Securities and Exchange Commission or any state securities commission or regulatory authority, nor has any commission or regulatory authority confirmed the accuracy of the information contained in the offering materials.
The information is provided for convenience only, is not investment advice and may not be relied upon in considering an investment in WEED, Inc. No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research. No representation or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment. In addition, prospective investors are encouraged to consult with their financial, tax, accounting or other advisors to determine whether an investment in WEED, Inc. is suitable for them.
Media Contact:
Glenn E. Martin, CEO
1-520-818-8582
Glenn@WEEDincUSA.com
Investor Contact:
First Apex International
Investors@WEEDincUSA.com
SOURCE: WEED, Inc.
WEED Inc. 'SALUTES' our Veterans & Arizona's Historic VOTE
Press Release | 11/11/2020
Congratulations: New Jersey, Montana, South Dakota & Mississippi
Fully legal in 15 States , "ALL Fifty States in 50 Months" #LegalizeNow
TUCSON, AZ / ACCESSWIRE / November 11, 2020 / WEED, Inc. (OTCQB:BUDZ), the holding company focused on the development and application of cannabis-derived compounds for the treatment of human diseases has continued its pursuit of developing and acquiring intellectual property and trademark rights, along with product development strategies for both domestic and global markets.
"After 50+ years of advocacy, I've lived to see legalization for Natures Healing Plant Cannabis in all its forms" declares WEED's CEO Glenn E. Martin. "With the recent election results, I believe Arizona will be brought to the forefront for potential new therapies, treatments and eventual cures for many diseases, both man & beast, utilizing ‘next' generation cannabis genetics and medical cannabis breakthroughs" Martin continues, "Our veterans served & died for our Freedom, to use cannabis and other natural medicines. Now its Americas time to Honor our VETS with full legalization."
!BEARDOWN AZ - CONGRATULATIONS!
WEED 2020 updates:
Nicole Breen WEED's Sec/Treas. commented; "WEED, Inc. filed for a Regulation A+ offering with S.E.C. on February 11th, 2020 and is anxious to begin its offering, hopefully in the near future . Due to the current pandemic, WEED's national/International projects, studies and Doctors Education programs are currently on hold. I wish to assure our shareholders that we have kept current with all obligations, no personnel have been laid off or terminated". Mrs. Breen continued, "Everyone's safety & security is our utmost concern and priority in making decisions moving forward with product development and international expansion." WEED's management also announced the following additional updates:
2 previously filed litigations in Colorado & Arizona have been successfully defended with both suits being terminated to the benefit of WEED Inc shareholders. There is no current or pending litigation.
WEED's acquisition of the Sugar Hill Golf course in Western New York is on schedule to close Feb 1st. 2021, assuming WEED raises the additional funds for the closing. WEED looks to eventually utilize the property to develop an infused beverages & edibles research division, with hemp/cannabis products planned for the NY marketplace & beyond.
WEED Australia Ltd. has completed its 2017 & 2018 audits from KPMG Australia. This important milestone, as a regulated ASIC company, are essential in moving forward with planned public offerings in 2021. (Fiscal year ends June 30) Year 2019 & 2020 audits are underway. Wildfires & Covid-19 have slowed the process due to restricted air travel.
About WEED Australia Ltd. and The Cannabis Institute of Australia
WEED Australia Ltd.'s corporate strategy is to become a leader in cannabis/hemp research and product development. To support this goal WEED Australia Ltd. has assembled a highly qualified team of well-respected Ph.D.'s, scientists, researchers and business experts with the goal of establishing domestic use and export industries for Australians.
About WEED Israel (Cannabis) Ltd.
WEED Israel Cannabis Ltd. looks to complete Patent & Trademark acquisitions, start human clinical trials once Covid-19 is defeated and WEED Israel can start-up safely again to develop both Pharmaceutical & non-pharmaceutical products for domestic use and International exports.
WEED Israel Cannabis Ltd. was established to build and expand WEED, Inc.'s global presence. In support of WEED Israel Cannabis Ltd., WEED, Inc. had entered into an exclusive license and assignment agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, Israel. The agreement was for five patents, technology and know-how relating to formulations for the administration and delivery of cannabinoid compounds has been terminated. These patents were developed by Prof. Elka Touitou at the Hebrew University of Jerusalem and will be reviewed once over Covid-19 pandemic & Israeli regulations are clarified.
About Sangre AT, LLC dba Sangre BioSciences.
Sangre AT, LLC (dba "Sangre BioSciences"), WEED, Inc.'s wholly owned US subsidiary, is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre BioSciences, please visit www.WEEDincUSA.com
About WEED Hong Kong Limited:
WEED Hong Kong Limited was established April 23rd, 2019 as an International subsidiary of WEED Inc USA. A special purpose holding company for development of our Patents, Trademarks, Copyrights and intellectual Property for company and brands of WEED Inc. on a global basis. Glenn E Martin, Director, President, CEO. Nicole Marie Breen, Director and company Treasurer. Ed Lehman, of Lehman, Le and Xu Corporate Services Limited, is appointed the corporate secretary. Registered office: Lehman, Lee and Xu. Suite 3313, Tower One, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong. WEED Hong Kong Limited, has maintained its corporate presence but kept dormant due to Covid-19 pandemic.
About WEED, Inc.
WEED, Inc. (BUDZ) is currently a USA-based fully reporting public company, quoted on the OTCMarkets. (OTCMarkets.com) WEED Inc. is a multi-national, multi-faceted, vertically integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brands.
WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments, therapies and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locations. For additional information about WEED Inc, please visit: www.WEEDIncUSA.com
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of WEED, Inc.'s securities, here or abroad, nor shall there be any sale of the shares of common stock in any state or country in which offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.
Forward-Looking Statements:
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions.
Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process, along with control of the global Covid-19 pandemic.
For more information, contact:
Glenn E. Martin
(520) 818-8582
info@WEEDIncUSA.com
SOURCE: WEED, Inc.
WEED, Inc. and Yissum (of the Hebrew University of Jerusalem) sign first-of-its-kind deal for exclusive license, assignment and transfer to WEED Inc. of groundbreaking intellectual property for novel technologies and formulations of cannabis-related and cannabinoid-based products
TUCSON, AZ / ACCESSWIRE / March 7, 2019 / WEED, Inc., (BUDZ) ("WEED") announced today that it has entered into an exclusive license and assignment agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem Ltd., Israel ("Yissum").
Under the terms of the agreement, WEED, Inc. agrees to exclusively license and, purchase from Yissum, certain patents, technology and know-how (upon payment of certain installments) relating to formulations for the administration and delivery of lipophilic compositions (including cannabinoids) developed by Prof. Elka Touitou at the Hebrew University of Jerusalem. Under the agreement, WEED is obligated to pay multi-million dollar consideration to Yissum , which is payable in installments and includes a product sales-related milestone payment, with WEED only receiving the exclusive license rights and the assignment rights to the above intellectual property after payment of the relevant installment payments. In order to close the exclusive license portion of the agreement and the assignment portion of the agreement, WEED, Inc. needs to raise additional funds to pay the consideration required under the agreement.
WEED Inc. is also pleased to announce that it has entered into a consulting agreement with Prof. Elka Touitou, of the Institute of Drug Research, School of Pharmacy, The Hebrew University of Jerusalem.
Prof. Touitou will serve as the chairperson of WEED, Inc.'s Scientific Advisory Board and will advise and support WEED, Inc. with respect to its scientific research and product development for this project.
Mr. Glenn E. Martin, CEO of WEED, Inc. said, "WEED, Inc. has made history in the Holy Land! After several months of intense and productive negotiations along with several trips to Israel, WEED and Yissum have successfully concluded this multi-million USD exclusive license and assignment agreement."
"Further I'm pleased to announce that we believe this historic arrangement with WEED, Inc. and its wholly owned subsidiary WEED Israel Cannabis Ltd., for this exclusive license and assignment of five patent families held by Yissum based on the innovations of Professor Elka Touitou, will now allow us to move forward to help and benefit patients. Prof Touitou is a pioneer in cannabinoid research, and published the first scientific work on transdermal delivery of cannabinoids in 1988. Our researchers are looking to develop efficient products for at least two ‘indications,' one of which will be focused on woman's health, utilizing Cannabinoids."
Dr. Yaron Daniely, CEO and President of Yissum stated, "As global leaders in the field of Cannabis and Endocannabinoid research, Yissum diligently looks for appropriate commercial partners to advance promising technologies from Hebrew University for the benefit of patients. We are hopeful that this partnership delivers important new products and therapies to those in need."
Elliott Kwestel, Director and Corporate Secretary of WEED Israel Cannabis Ltd. commented, "WEED Israel is looking to acquire all appropriate licenses with the goal of bringing vertically integrated products to market globally within one year. Further studies in high dosage THC, THC and continuing CBD research are on the horizon."
The assignment of the five patent families to WEED, Inc. pursuant to the agreement with Yissum, is the first-of-its-kind originating from Cannabinoid research conducted at The Hebrew University of Jerusalem.
Prof. Touitou said, "Cannabinoids are very lipophilic molecules with a relative low bioavailability, short activity and their existing formulations often have low patient compliance. There is a great need and demand for pharmaceutical products with improved efficacy and prolonged therapeutic effect. Our new sophisticated technologies offer diverse solutions for promoting enhanced delivery and adequate administration of Cannabinoids for high therapeutic efficiency in treating patients currently suffering from various diseases."
Dr. Liat Shbiro PhD added, "It's an incredible privilege to work with Professor Touitou who shall lead WEED Israel's cannabis research and chair our Israeli Scientific Advisory Board."
In this deal, WEED Inc. was represented by the law firm of Snell & Wilmer L.L.P., Phoenix, Arizona, USA and Marcella Eytan and Nir Zohar of the law firm Pearl Cohen Zedek Latzer Baratz, Tel-Aviv, Israel.
About Yissum Research Development Company of the HebrewUniversity of Jerusalem Ltd.
About Yissum
Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the third company of its kind to be established and serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissum's mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 10,700 patents covering 3,000 inventions; licensed over 950 technologies and has spun out more than 150 companies. Yissum's business partners span the globe and include companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson, Merck, Microsoft, Novartis and many more. For further information please visit www.yissum.co.il
About Prof. Elka Touitou
Prof. Elka Touitou is the Head of the Innovative Dermal, Transdermal and Transmucosal Delivery Lab at the Institute of Drug Research, The School of Pharmacy, HUJ.
Professor Touitou is an internationally renowned authority in the field of drug delivery and design of new technologies for efficient administration of drugs and development of new products. She has pioneered leading technologies in the field, being the inventor of Ethosomes, currently recognized as one of the most sophisticated and efficient transdermal carriers. Professor Touitou is a Visiting Professor at Universities in Europe and Asia. She has broad experience in collaborating with the pharmaceutical industry serving in their Advisory Boards.
Professor Touitou has served as a Director in the Board of Controlled Release Society (CRS) and is honored as a CRS Fellow, recipient of the Jorge Heller Outstanding Paper Award, the Kaye Award for Innovation and honored as one of leader innovators at the Hebrew University.
Professor Touitou has more than 100 scientific publications that include original research papers, reviews and book chapters. She is a co-editor of the books Enhancement in Drug Delivery (2006) and Novel Cosmetic Delivery Systems (1999). She is also the author of numerous granted international patents.
About WEED, Inc.
WEED, Inc. (BUDZ) is currently a USA-based fully reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments, therapies and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locations. For additional information about WEED Inc, please visit: www.WEEDIncUSA.com
About Sangre AT, LLC DBA Sangre BioSciences.
Sangre AT, LLC (dba "Sangre BioSciences"), WEED, Inc.'s wholly owned US subsidiary, is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre BioSciences, please visit www.sangreagrotech.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of WEED, Inc.'s securities, here or abroad, nor shall there be any sale of the shares of common stock in any state or country in which offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.
Forward-Looking Statements:
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Glenn E. Martin at (520) 818-8582 or info@WEEDIncUSA.com
SOURCE: WEED, Inc.
Tuesday, December 11, 2018 10:55 AM
WEED's ''End-of-Year Scientific Research Conference'' brings successful results to it's 5-year Comprehensive Cannabis Integrated Molecular Breeding Platform
TUCSON, AZ / ACCESSWIRE / December 11, 2018 / WEED, Inc. (OTCQB: BUDZ) (the ''Company'') or (''WEED'') announced that its first of many cultivar DNA sequencing tests have been perfected and finalized. WEED's team of scientists is currently going thru the analytics evaluation and reports are forthcoming. ''During this time our team designed, tested, and refined standard operating procedures for efficient DNA isolation and sequencing of Cannabis genomes. Extensive bioinformatics analysis of repeatable and variable regions has been performed on newly-generated DNA sequencing data of 26 landrace cultivars and several publicly available genomes.'' stated CEO, Glenn E Martin.
Dr. George Golovko & Dr. Kamil Khanipov of Industrial Metagenomics stated goals for WEED, include, but are not limited to, ''this is the first phase of the Company's announced 5-year genomic research study, the results of this analysis will allow WEED Inc. to move forward towards a guided breeding program to further extend the development of a comprehensive genomic resource for effective breeding and identification of Cannabis plants.''
Dr. George commented further, ''The first part of the second phase of the program will include the development of a reference genome and transcriptome which will serve as a representative. The references will be used for genotyping to generate a range of proprietary data and suite of products accessible exclusively to WEED Inc.''
''Completion of these tasks will allow WEED, Inc. to create a Universal Genotyping Assay (UGA) for Cannabis cultivars to genetically identify and classify cultivars in a low-cost high throughput manner. The UGA will be a vital component in the decision-making process for robotic molecular breeding systems.'' added Dr Khanipov.
The final goal of the genomic studies is the development of a database for the Comprehensive Molecular Breeding Platform connecting cultivar's properties (e.g., THC, CBD, disease resistance, acceptable growth conditions) and their genetic signatures. To achieve these goals, WEED Inc is planning to design a genotyping assay to determine the cultivar's genetic profile and be able to perform comprehensive molecular-based breeding of thousands of cultivars in a quick and inexpensive way. The Company expects that this data, in concert with cultivar's chemical profiles, will allow it to computationally predict Quantitative Trait Loci (a region of the genome that correlates to plant's traits). A database of these genomic regions, QTLs, and associated chemical profiles comprehensive knowledge base will be the key to create ''designer'' cultivars.
WEEDs ''End-of-Year conference''. will include, WEED's group of highly skilled PHDs flying in from around the country to Tucson December 19th thru 22nd. Also, via satelite, WEEDS Phd teams from WEED Israel Cannabis Ltd., & WEED Australia Ltd will attend.
About WEED, Inc.
WEED, Inc. (OTCQB: BUDZ) is currently a USA-based fully reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments, therapies and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locations. For additional information about WEED, Inc., please visit www.WEEDIncUSA.com.
About Sangre AT, LLC
Sangre AT, LLC (dba "Sangre AgroTech") is a wholly-owned subsidiary of WEED, Inc., and is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre AgroTech, please visit www.sangreagrotech.com.
Forward-Looking Statements:
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Glenn E. Martin at (520) 818-8582
glenn@WEEDIncUSA.com
SOURCE: WEED, Inc.
Thursday, October 18, 2018 11:55 AM
Acquisition of the Trademarks Part of the Company's Plan to Acquire Intellectual Property Relevant to the Industry when Practical
TUCSON, AZ / ACCESSWIRE / October 18, 2018 / WEED, Inc. (OTCQB: BUDZ), a global Cannabis holding company focused on the development and application of cannabis–derived compounds for the treatment of human diseases, announced today that it has acquired the rights to two trademark registrations directed to the name of the company, WEED.
The marks, which were acquired by WEED, Inc. from Copalix (PTY) Ltd., a private South African company, were assigned in the United States Patent Office and European Union Intellectual Property Office, respectively, on May 29 and August 14 of this year. The acquisitions include the purchase of a United States Trademark Registration (U.S. Trademark Registration No. 4,927,872) for the wordmark "WEED®" for pouches for carrying electronic cigarettes, mouth pieces for electronic cigarettes, and wicks for electronic cigarettes and a European Trademark Registration (European Community Trademark Registration No. 11953387) for the same wordmark "WEED®" for batteries and electronic accumulators, batteries for electronic cigarettes, chargers for electric cigarettes, battery chargers for electron cigarettes, USB chargers, car chargers, parts and fittings for the aforesaid goods and matches, pouches for carrying electronic cigarettes, mouth pieces for electronic cigarettes, rechargeable cigarette cases along with their parts and fittings.
The purchases are part of a broader effort by WEED, Inc. to expand its Intellectual Property (IP) Brands Division into a variety of goods and services outside those offered as part of its core goods and services, namely, the development of cannabis–derived healthcare & adult use Cannabis products. Among other measures, WEED, Inc. has sought to expand WEED™ and other associated brands including WEED RULES!™ to goods and services that include cosmetics and cleaning preparations, paper goods and printed matter, and natural agricultural products in addition to others through the filing of multiple trademark applications in the United States Patent and Trademark Office. "We are hopeful that such actions to protect existing rights and acquire future intellectual property rights will fortify WEED, Inc.'s position as a leader in the cannabis industry, creating shareholder value above and beyond the the value created by the company's core business," comments WEED, Inc. President/CEO Glenn E. Martin. "We believe the majority of discoveries in Cannabis are yet to be found. I believe these exciting times will not only change global health but the penetrate many markets worldwide! WEED'S leading scientists are already working on new breeding programs, genetic modifications, formulations and drug delivery systems for both humans and pets."
About WEED, Inc.
WEED, Inc. along with its subsidiary, Sangro AT, LLC, is an early stage cannabis holding company, which focuses on the development and application of cannabis-derived compounds for the treatment of human disease with a goal of identifying, collecting, and archiving a collection of medicinal cannabis strains. It also focuses on purchasing land and building commercial grade cultivation centers to consult, assist, manage, and lease to dispensary owners and organic grow operators. WEED, Inc. is based out of Tucson, Arizona and more information can be found on the corporation's website at www.WEEDInc.co.
About Sangre AT, LLC
Sangre AT, LLC (dba "Sangre AgroTech") is WEED, Inc.'s wholly-owned subsidiary and is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre AgroTech, please visit www.sangreagrotech.com.
Forward-Looking Statements:
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Glenn E. Martin at (520) 818-8582 or info@WEEDInc.co
SOURCE: WEED, Inc.
Monday, September 10, 2018 5:55 AM
WEED, Inc. Forms WEED Israel (Cannabis) Ltd, WEED Australia Ltd, and Cannabis Institute of Australia...
TUCSON, AZ / ACCESSWIRE / September 10, 2018 / WEED, Inc. (OTC PINK: BUDZ) (the "Company" or "WEED"), has established WEED Israel (Cannabis) Ltd. as a wholly owned subsidiary of WEED Inc (USA). WEED Israel (Cannabis) Ltd. is currently in negotiations with major universities, hospitals, charitable organizations, Kibbutz, and private & public entities to create a true "SEED-TO-SALE" company from this Holy Land. WEED Israel's goal is to educate the medical community with treatments and therapies to stop opioid dependency for military and public, to service the Israeli domestic Cannabis medical market, WEED Israel (Cannabis) Ltd. plans to work closely with the Israeli Ministry of Health, to grow its cannabis export markets.
WEED Israel (Cannabis) Ltd. President/CEO Glenn E. Martin proclaims that "At least 50% of any profits from operations in Israel will remain in Israel to create/expand new medicinal therapies & treatments for the Israeli people suffering from ailments and opioid destruction. WEED Israel looks to establish the 'GOLD STANDARD' model to make sure Israel receives its fair share and not to be exploited by large Canna-pharma companies from overseas."
"Unique in the cannabis research world, Israel has been in the forefront of the industry since the early 1960's. We believe Israel can show the world that the dedication and hard work of its top researchers over the last few decades has created new Cannabis discoveries, including everything from delivery systems for humans and pets to creating new Cannabis Sativa strains to alleviate pain and ailments for human diseases," states Executive VP, Mr. Elliot Kwestel.
Mr. Kwestel, WEED Israel (Cannabis) Ltd.'s Director, Secretary and Executive VP for domestic and International development comments, "The cures are out there, we believe you'll find them in WEED."
WEED Australia Ltd., established in March 2017, was one of only a handful of cannabis companies in Australia at the time and the first and only subsidiary of a United States-based public company in Australia. WEED Australia Ltd.'s goal is an IPO in 2019. WEED Australia Ltd. formed its nonprofit division, The Cannabis Institute of Australia in March 2018, with the goal of creating (i) a Scientific Advisory Council to establish National protocols and procedures backed by scientific research to perfect strain specific, disease-specific treatments, therapies and prayed for cures, (ii)
a network of PHD's and doctors across Australia, from Brisbane & Perth, to educate and oversee clinical trials, protocols and procedures for both humans & animals, (iii) medical discoveries & products to conquer the opioid addiction with natural remedies. Educating MD's & naturopathic doctors, are key to implementing a National Cannabis Medical program, and (iv) Australia's finest export industry for cannabis and hemp products to maximize its curative power while minimizing its cost to the world.
WEED Inc (USA) is a fully reporting, PCAOB audited, Sarbanes-Oxley compliant, world-class cannabis corporation with corporate offices in Israel, Australia and United States of America.
WEED Inc. (BUDZ) established its wholly owned subsidiary; WEED Israel (Cannabis) Ltd. (2018). #515884567
WEED Australia Ltd. (2017) ACN: 617 827 764 and its wholly owned nonprofit arm;
The Cannabis Institute of Australia (C.I.A,) in Q1 2018. ACN:625 492 113
The Cannabis Institute is wholly owned by WEED Australia Ltd.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of WEED, Inc.'s securities, here or abroad, nor shall there be any sale of the shares of common stock in any state or country in which offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.
About WEED, Inc.
WEED, Inc. (OTCQB: BUDZ) is currently a USA-based fully reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments, therapies and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locations. For additional information about WEED, Inc., please visit www.WEEDInc.co
About Sangre AT, LLC
Sangre AT, LLC (dba "Sangre AgroTech") is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre AgroTech, please visit www.sangreagrotech.com.
Forward-Looking Statements:
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Glenn E. Martin at (520) 818-8582 or info@WEEDInc.co
SOURCE: WEED, Inc.
Monday, August 13, 2018 12:30 PM
TUCSON, AZ / ACCESSWIRE / August 13, 2018 / WEED, Inc. (OTC PINK: BUDZ) (the "Company" or "WEED"), a current alternative reporting public company focused on the development and application of cannabis-derived compounds for the treatment of human disease, announced that its Form S-1 resale registration statement relating to the resale of up to 8,982,015 shares of its common stock by certain selling shareholders (the "S-1") was declared effective by the Securities and Exchange Commission on August 8, 2018 at 4pm Eastern Time.
The S-1 will, while effective, allow the selling shareholders listed in the S-1 to resell their shares of WEED, Inc.'s common stock, subject to the prospectus delivery requirements of the Securities Act of 1933, as amended, in connection with any such resale. As noted in the S-1, the selling shareholders in the S-1 may sell their shares registered for resale pursuant to the Prospectus. WEED, Inc. will not receive proceeds from the sale of the common stock by the selling shareholders.
The offering of the shares of common stock may only be made by means of a prospectus. A registration statement relating to the shares has been declared effective by the Securities and Exchange Commission. The registration statement may be accessed electronically through the SEC's website at www.sec.gov. A copy of the prospectus related to the offering may also be obtained from WEED, Inc. by writing to 4920 N. Post Trail, Tucson, AZ 85750, by calling (520) 818-8582, or by e-mailing info@WEEDInc.co.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of WEED, Inc.'s securities, nor shall there be any sale of the shares of common stock in any state in which offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About WEED, Inc.
WEED, Inc. (OTC PINK: BUDZ) is currently a USA-based alternative reporting public company. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. subsidiaries in foreign locations. For additional information about WEED, Inc., please visit www.WEEDInc.co.
About Sangre AT, LLC
Sangre AT, LLC (dba "Sangre AgroTech") is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre AgroTech, please visit www.sangreagrotech.com.
Forward-Looking Statements:
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Glenn E. Martin at (520) 818-8582 or info@WEEDInc.co
SOURCE: WEED, Inc.
Tuesday, March 13, 2018 5:40 PM
Subsidiary, Sangre AgroTech, Receives Commercial Redevelopment Permit for BioScience Research Center in La Veta, Colorado
TUCSON, AZ / ACCESSWIRE / March 13, 2018 / WEED, Inc. (OTC PINK: BUDZ) (the "Company" or "WEED"), a current alternative reporting public company focused on the development and application of cannabis-derived compounds for the treatment of human disease, announced that it has completed the previously announced purchase of its 4-acre property in La Veta, Colorado, where its wholly-owned subsidiary, Sangre AgroTech, is engaged in the previously announced 5-year, $15+ million Cannabis Genomic Study. Under the terms of the original purchase agreement, the Company paid $525,000 down, including 25,000 shares of common stock, and was obligated to pay an additional $400,000 in cash and issue an additional 75,000 shares of common stock over the next two years in order to pay the remainder of the purchase price. On January 12, 2018, the Company entered into an amendment to the $475,000 principal amount promissory note issued by the Company to the seller of the property in connection with the original purchase agreement, under which both parties agreed to amend the purchase and the promissory note to allow the Company to pay off the note in full if $100,000 in cash was paid on or before January 15, 2018 and the seller was issued 125,000 shares of the Company’s common stock, restricted in accordance with Rule 144, on before January 20, 2018. The Company carried out the actions outlined in the amendment leading to full satisfaction of all amounts owed by the Company under the note, in exchange for a full release of the deed of trust that was securing the promissory note. The Company now owns the La Veta property without encumbrances.
In connection with the La Veta, CO, property, the Company received unanimous approval of the La Veta Town Council for a Commercial Redevelopment Permit to begin planned renovations and construction of the Bioscience Research Center for the operations of Sangre AgroTech to convert the existing buildings into laboratory facilities necessary for Sangre to conduct its research, along with additional security and ground buildout. Initial property renovations are expected to be completed by the end of Q3 of 2018 at a cost of $1.3M. And the full buildout is currently scheduled for the end of Q1 2019, at an additional cost of $3.13M. In order to complete these buildouts, the Company will need to raise additional funds. Additionally, approximately $1.5M of scientific equipment has been ordered for genomic sequencing and product extraction. Dr. Patrick Williams, President and Chief Science Officer of Sangre AgroTech, stated, “We are excited to begin the buildout of our bioscience research facility, and look forward to our staff working in the new state-of-the-art laboratory facilities we are constructing. We plan to utilize the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available."
The Company also announced that it has extended its offer to purchase approximately 43 acres of property located in Westfield, New York for a total purchase price of $800,000. This property has unlimited water extraction rights from the State of New York. The Company plans to use this property as they progress into the New York hemp and infused beverage markets in the future. The property acquisition is expected to close May 1, 2018.
The Company announced that it conducted its first 2018 Board of Directors meeting in Tucson, AZ, on January, 23, 2018, where it discussed the establishment of an Executive Committee, approved compensation packages and consulting agreements, ratified and confirmed the appointment of attorneys for trademark work and Canadian operations, and approved real estate acquisitions.
The Company announced that it purchased on January 3, 2018, a condominium in La Veta, CO, for the purchase price of $140,000 in cash, and was acquired for the purpose of housing personnel who are vital to the 5-year Cannabis Genomic Study.
About WEED, Inc.
WEED, Inc. (OTC PINK: BUDZ) is currently a USA-based alternative reporting public company that filed an S-1 Registration with the SEC on August 11, 2017. WEED Inc. is a multi-national, multi-faceted, vertically-integrated world class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote our global brand. WEED is dedicated to its global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant family. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act, and meets all standards of international law for WEED, Inc. subsidiaries in foreign locations. For additional information about WEED, Inc., please visit www.weedin.co.
About Sangre AT, LLC
Sangre AT, LLC (dba "Sangre AgroTech") is a plant genomic research and breeding company comprised of top-echelon scientists with extensive expertise in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. For additional information about Sangre AgroTech, please visit www.sangreagrotech.com.
Forward-Looking Statements:
This release contains forward-looking statements. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could," or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Glenn E. Martin at (520) 818-8582 or info@weedinc.co
SOURCE: WEED, Inc.
